Form 4 for NVCR NovoCure Ltd
Accepted 2025-06-06 00:00:00 ET · period of report 2025-06-04 · accession 0001562180-25-004553 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-06 | 2025-06-04 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $0.00 | +179.4K | 347.9K | +107% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-06-04 | A | A | 179,426 | $0.00 | 347,878 | D | — | — | (F1) Represents restricted share units that are scheduled to vest in equal installments on June 4, 2026 and 2027, subject to the reporting person's continued employment through such dates. |